Trials / Completed
CompletedNCT00129961
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sirolimus | |
| DRUG | cyclosporine or tacrolimus |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2005-08-12
- Last updated
- 2012-04-11
- Results posted
- 2012-03-23
Locations
23 sites across 4 countries: United States, Australia, Canada, New Zealand
Source: ClinicalTrials.gov record NCT00129961. Inclusion in this directory is not an endorsement.